# Custom synthesis (CDMO): Production

Why peptide and ADC capacity is tight while other lines idle

Source page: https://www.materialinsights.org/chemicals/custom_synthesis/production/

What this tab covers Who makes it and how much: world capacity and output, utilisation, the top producing countries and companies globally and in India, concentration, new capacity coming, and each region's position.

| Measure | Figure | Detail | Source |
|---|---|---|---|
| **World capacity** | not published in aggregate |  |  |
| **World output** | revenue about $173.7 billion (2025) |  | Global Market Insights via GEN |
| **Capacity utilisation** | not published | Small-molecule capacity was loose in 2023-2025 after COVID; peptides and ADCs tight. | qualitative |
| **Concentration** | top-10 CDMOs about 20% of the $173.7 billion market (derived: $35.1 billion / $173.7 billion) | The market is fragmented outside biologics. | GEN (2026); derived |
| **New capacity** | capex: Divi's Rs 25.4 billion in FY26; Laurus capex 16% of sales; Bachem over CHF 400 million in 2026 | Divi's Kakinada Unit 3 (planned Rs 15 billion, Rs 6 billion capitalised); Laurus Vizag fermentation and API capacity; Piramal $90 million US expansion (Lexington, Riverview); Lonza considering $1 billion Ohio plant; Samsung bought a GSK site in Rockville for $353 million. | BoB (May 2026); Laurus FY26; IntuitionLabs (2026); GEN (2026) |

#### Top producing countries

- **United States**: Thermo Fisher $7.1 billion (2025 estimate), Catalent (Novo Holdings)
- **Switzerland**: Lonza CHF 6.53 billion, Siegfried CHF 1.33 billion, Bachem CHF 0.70 billion (2025)
- **China**: WuXi AppTec RMB 45.45 billion, WuXi Biologics RMB 21.79 billion (2025)
- **South Korea**: Samsung Biologics KRW 4.557 trillion (2025)
- **Japan**: Fujifilm Biotechnologies JPY 257.2 billion; AGC Biologics JPY 129.4 billion (FY2025)
- **India**: Divi's Rs 105.6 billion total (FY26), Piramal CDMO Rs 4,915 crore, Syngene Rs 3,739 crore, Laurus CDMO Rs 2,080 crore
 GEN (2026); GEN (2026); Bachem; BoB; IntuitionLabs; Syngene; Laurus

#### Largest producers: global

| Company | Country | Volume | Year | Source |
|---|---|---|---|---|
| **Lonza** CORE EBITDA margin 31.6%; 2026 guidance 11-12% CER growth | Switzerland | 6.531 CHF billion sales (continuing CDMO) | 2025 | [Lonza Full-Year Results 2025](https://links.sgx.com/1.0.0/corporate-announcements/JX40DSPFWE3XG83V/873320_20260128_Lonza%20Full-Year%20Results%202025_FINAL%20compressed.pdf) |
| **Thermo Fisher (Pharma Services)** | US | 7.142 $ billion revenue (estimate) | 2025 | [GEN Top 10 CDMOs 2026](https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2026/) |
| **WuXi AppTec** H1 2026 revenue up 38.9%; 2026 guidance RMB 58.5-60.5 billion | China | 45.45 RMB billion revenue | 2025 | [GEN Top 10 CDMOs 2026](https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2026/) |
| **WuXi Biologics** | China | 21.79 RMB billion revenue | 2025 | [GEN Top 10 CDMOs 2026](https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2026/) |
| **Samsung Biologics** bidding CHF 1.46 billion for PolyPeptide | South Korea | 4.557 KRW trillion revenue | 2025 | [GEN Top 10 CDMOs 2026](https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2026/) |
| **Siegfried** small-molecule focus | Switzerland | 1.328 CHF billion revenue | 2025 | [GEN Top 10 CDMOs 2026](https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2026/) |
| **Bachem** peptides and oligos | Switzerland | 695 CHF million sales | 2025 | [Bachem FY2025](https://www.bachem.com/wp-content/uploads/2026/03/Media-Release-Financial-Year-2025_final.pdf) |

#### Largest producers: India

| Company | Country | Volume | Year | Source |
|---|---|---|---|---|
| **Divi's Laboratories** custom synthesis up 15.8% YoY; FY26 group revenue Rs 105.6 billion, EBITDA margin 32.6% | India | 15.3 Rs billion custom synthesis sales in Q4 FY26 | FY26 | [BoB Capital Q4 FY26 review](https://www.barodaetrade.com/Reports/DivisLabs-Q4FY26ResultReview24May26-Research.pdf) |
| **Piramal Pharma Solutions** down 10% on destocking; 15 sites | India | 4,915 Rs crore CDMO revenue | FY26 | [IntuitionLabs](https://intuitionlabs.ai/articles/top-cdmo-companies-2026-ranked) |
| **Syngene International** EBITDA margin 25% (29% in FY25) | India | 3,739 Rs crore revenue | FY26 | [Syngene Q4 FY26 press release](https://www.syngeneintl.com/wp-content/uploads/2026/04/Syngene-Press-Release-Q4-FY26.pdf) |
| **Laurus Labs (CDMO)** up 36% | India | 2,080 Rs crore CDMO revenue | FY26 | [Laurus FY26 press release](https://www.lauruslabs.com/Investors/PDF/PressReleases/PressRelease-Laurus-Labs-Announces-Full-Year-FY26-Results-Revenues-at-₹6_813Cr_EBITDAat₹1_826Cr_ 26.8_ margins.pdf) |
| **Cohance Lifesciences (formerly Suven Pharmaceuticals)** Suven merged with Cohance (Advent International); FY26 figures not found | India | not published | FY26 | not found |

Indian CDMOs are small next to Lonza or WuXi (Divi's, the largest, had total FY26 revenue of about $1.2 billion at Rs 88/$). Their advantages are cost, chemistry talent and a non-Chinese location; their gaps are biologics scale and early-stage pipelines.

#### Position by region

| Region | Position |
|---|---|
| **US** | BIOSECURE Act steers federally funded work away from listed Chinese firms; 5-year grandfathering of existing contracts after FAR rules. |
| **EU** | Lonza, Siegfried, Bachem, Recipharm benefit from reshoring. |
| **India** | Positioned as China-plus-one; FY26 results mixed. |
| **China** | WuXi still growing fast (H1 2026 +38.9%) despite US pressure. |
| **Japan** | Fujifilm and AGC in biologics. |
| **Middle East** | 2026 crisis raised raw material costs for Indian CDMOs (BoB on Divi's). |

## Other sections

- [Summary](https://www.materialinsights.org/chemicals/custom_synthesis/index.md)
- [Overview](https://www.materialinsights.org/chemicals/custom_synthesis/overview/index.md)
- [Correlation](https://www.materialinsights.org/chemicals/custom_synthesis/correlation/index.md)
- [Production route](https://www.materialinsights.org/chemicals/custom_synthesis/routes/index.md)
- [Feedstocks](https://www.materialinsights.org/chemicals/custom_synthesis/feedstocks/index.md)
- [Cycles](https://www.materialinsights.org/chemicals/custom_synthesis/cycles/index.md)
- [Trading](https://www.materialinsights.org/chemicals/custom_synthesis/trading/index.md)
- [Movement](https://www.materialinsights.org/chemicals/custom_synthesis/movement/index.md)
- [Regulation](https://www.materialinsights.org/chemicals/custom_synthesis/regulation/index.md)
- [Characteristics](https://www.materialinsights.org/chemicals/custom_synthesis/characteristics/index.md)
- [Emissions](https://www.materialinsights.org/chemicals/custom_synthesis/emissions/index.md)
- [Relationships](https://www.materialinsights.org/chemicals/custom_synthesis/links/index.md)